Eli Lilly PE Ratio 2010-2024 | LLY
Current and historical p/e ratio for Eli Lilly (LLY) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Eli Lilly PE ratio as of December 20, 2024 is 77.59.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Eli Lilly PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-12-20 |
767.76 |
|
83.00 |
| 2024-09-30 |
884.40 |
$9.25 |
95.61 |
| 2024-06-30 |
902.55 |
$8.12 |
111.15 |
| 2024-03-31 |
774.25 |
$6.79 |
114.03 |
| 2023-12-31 |
579.14 |
$5.80 |
99.85 |
| 2023-09-30 |
532.66 |
$5.52 |
96.50 |
| 2023-06-30 |
464.11 |
$7.19 |
64.55 |
| 2023-03-31 |
338.97 |
$6.29 |
53.89 |
| 2022-12-31 |
359.93 |
$6.90 |
52.16 |
| 2022-09-30 |
317.25 |
$6.66 |
47.64 |
| 2022-06-30 |
317.11 |
$6.27 |
50.58 |
| 2022-03-31 |
279.14 |
$6.75 |
41.35 |
| 2021-12-31 |
268.13 |
$6.14 |
43.67 |
| 2021-09-30 |
223.55 |
$6.56 |
34.08 |
| 2021-06-30 |
221.35 |
$6.67 |
33.19 |
| 2021-03-31 |
179.39 |
$6.69 |
26.81 |
| 2020-12-31 |
161.45 |
$6.80 |
23.74 |
| 2020-09-30 |
140.80 |
$6.12 |
23.01 |
| 2020-06-30 |
155.41 |
$6.16 |
25.23 |
| 2020-03-31 |
130.70 |
$6.05 |
21.60 |
| 2019-12-31 |
123.19 |
$8.76 |
14.06 |
| 2019-09-30 |
104.21 |
$8.22 |
12.68 |
| 2019-06-30 |
103.24 |
$7.97 |
12.95 |
| 2019-03-31 |
120.26 |
$6.28 |
19.15 |
| 2018-12-31 |
106.68 |
$3.13 |
34.08 |
| 2018-09-30 |
98.42 |
$0.45 |
218.71 |
| 2018-06-30 |
77.83 |
$-0.14 |
0.00 |
| 2018-03-31 |
70.09 |
$1.06 |
66.12 |
| 2017-12-31 |
75.95 |
$-0.20 |
0.00 |
| 2017-09-30 |
76.44 |
$2.11 |
36.23 |
| 2017-06-30 |
73.08 |
$2.31 |
31.64 |
| 2017-03-31 |
74.21 |
$2.07 |
35.85 |
| 2016-12-31 |
64.46 |
$2.58 |
24.98 |
| 2016-09-30 |
69.88 |
$2.30 |
30.38 |
| 2016-06-30 |
68.14 |
$2.32 |
29.37 |
| 2016-03-31 |
61.89 |
$2.17 |
28.52 |
| 2015-12-31 |
71.92 |
$2.26 |
31.82 |
| 2015-09-30 |
70.99 |
$2.21 |
32.12 |
| 2015-06-30 |
70.40 |
$1.93 |
36.48 |
| 2015-03-31 |
60.84 |
$2.05 |
29.68 |
| 2014-12-31 |
57.37 |
$2.23 |
25.72 |
| 2014-09-30 |
53.53 |
$2.50 |
21.41 |
| 2014-06-30 |
50.91 |
$3.14 |
16.21 |
| 2014-03-31 |
47.81 |
$3.57 |
13.39 |
| 2013-12-31 |
41.05 |
$4.31 |
9.52 |
| 2013-09-30 |
40.12 |
$4.38 |
9.16 |
| 2013-06-30 |
38.81 |
$4.45 |
8.72 |
| 2013-03-31 |
44.48 |
$4.17 |
10.67 |
| 2012-12-31 |
38.28 |
$3.66 |
10.46 |
| 2012-09-30 |
36.42 |
$3.69 |
9.87 |
| 2012-06-30 |
32.59 |
$3.62 |
9.00 |
| 2012-03-31 |
30.22 |
$3.86 |
7.83 |
| 2011-12-31 |
30.80 |
$3.90 |
7.90 |
| 2011-09-30 |
27.05 |
$4.18 |
6.47 |
| 2011-06-30 |
27.08 |
$4.25 |
6.37 |
| 2011-03-31 |
25.06 |
$4.40 |
5.69 |
| 2010-12-31 |
24.61 |
$4.58 |
5.37 |
| 2010-09-30 |
25.31 |
$4.36 |
5.80 |
| 2010-06-30 |
22.90 |
$4.04 |
5.67 |
| 2010-03-31 |
24.42 |
$3.88 |
6.29 |
| 2009-12-31 |
23.73 |
$3.95 |
6.01 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$749.124B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
